Are there therapeutic implications of Msh2 in cancer treatment?
The presence or absence of Msh2 has significant therapeutic implications. Tumors with MMR deficiency, including those lacking Msh2, tend to respond well to immunotherapy, particularly checkpoint inhibitors like pembrolizumab. These drugs target the immune system's ability to recognize and attack cancer cells. The deficiency in Msh2 also affects the tumorâs response to traditional chemotherapies, as MMR-deficient tumors may exhibit resistance to certain agents like 5-fluorouracil.
